Swedish Orphan Biovitrum

125 articles about Swedish Orphan Biovitrum

• 

  AstraZeneca Continues to Divest Products, Sells Rights to RSV Drug to Sobi fo...

  11/14/2018

  Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion.

• FDA Accepts Investigational NDA and Grants Fast Track Status for Sobi's SOBI003 for the Treatment of MPS IIIA

  1/23/2018

  The clinical study with SOBI003 is expected to start during 2018.

• Invitation - Presentation Of Swedish Orphan Biovitrum's Q2 2017 Results

  7/6/2017

• Bioverativ And Swedish Orphan Biovitrum Highlight Commitment To Improving Care For People With Hemophilia At ISTH 2017 Congress

  7/6/2017

• Swedish Orphan Biovitrum Release: FDA Grants SOBI003 Orphan Drug Designation For The Treatment Of MPS IIIA

  7/5/2017

• Swedish Orphan Biovitrum Release: Xiapex Gets Recommendation To Be Made Available On National Health Service In England

  6/30/2017

• Swedish Orphan Biovitrum Release: EMA Approves The Potential To Dose Every 14 Days Or Longer In Updated Dosing Regimen For Alprolix

  6/27/2017

• Swedish Orphan Biovitrum - Orfadin Capsules Approved In The Kingdom Of Saudi Arabia For The Treatment Of Hereditary Tyrosinemia Type 1

  5/17/2017

• Swedish Orphan Biovitrum Release: First Patients Enrolled In 24 Month Real-World Study Evaluating Effectiveness Of Elocta

  1/19/2017

• Swedish Orphan Biovitrum: Elocta Approved in Kuwait For The Treatment Of Hemophilia A

  11/21/2016

• Swedish Orphan Biovitrum: European Study Of Real-Life Hemophilia Treatment Emphasizes Need To Improve Standard Of Care

  11/14/2016

• Swedish Orphan Biovitrum: Alprolix Approved In Switzerland For The Treatment Of Hemophilia B

  10/28/2016

• Swedish Orphan Biovitrum: European Commission (EC) Grants SOBI003 Orphan Designation For The Treatment Of MPS IIIA

  10/19/2016

• Swedish Orphan Biovitrum: Milan Zdravkovic Joins Sobi As Senior Vice President, Head Of Research & Development

  9/26/2016

• Swedish Orphan Biovitrum: Alprolix Obtains Reimbursement Across The United Kingdom

  9/26/2016

• Swedish Orphan Biovitrum: Elocta Obtains Reimbursement In UK, Italy And France, Complemented By Real-World Data And Extensive Patient Experience

  9/21/2016

• Swedish Orphan Biovitrum’s CEO Divests A Portion Of Shares

  8/9/2016

• Swedish Orphan Biovitrum: Sobi Publishes Its Report For The Second Quarter 2016

  7/15/2016

• Swedish Orphan Biovitrum's Board Of Directors Exercises Its Authorization For Repurchase Of Shares To Secure The Company’s Commitments Under The Incentive Programme

  7/15/2016

• Swedish Orphan Biovitrum: Health Canada Validates Orfadin Capsule Filing

  7/14/2016